Editorial

Drug-induced liver injury in clinical trials: As rare as hens teeth

Timothy J. Davern, Naga Chalasani

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Severe drug-induced liver injury is a relatively rare but important public health problem. Extrapolating the incidence of this problem from clinical treatment trials is confounded by a number of issues, including the relatively small size of clinical trials, exclusion criteria for study participation, and active surveillance for liver injury. Advances in understanding the pathogenesis of drug-induced liver injury, as well as its prevention and treatment, will likely require the identification and careful characterization of severe cases in the post-marketing, real-world setting as part of a concerted, multi-center, well-orchestrated effort. The Drug-Induced Liver Injury Network (DILIN) represents one example of such an effort.

Original languageEnglish
Pages (from-to)1159-1161
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume104
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Chemical and Drug Induced Liver Injury
Tooth
Clinical Trials
Marketing
Public Health
Liver
Incidence
Wounds and Injuries

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Editorial : Drug-induced liver injury in clinical trials: As rare as hens teeth. / Davern, Timothy J.; Chalasani, Naga.

In: American Journal of Gastroenterology, Vol. 104, No. 5, 05.2009, p. 1159-1161.

Research output: Contribution to journalArticle

@article{00ff719d115a477b8f34dceadfb36e7b,
title = "Editorial: Drug-induced liver injury in clinical trials: As rare as hens teeth",
abstract = "Severe drug-induced liver injury is a relatively rare but important public health problem. Extrapolating the incidence of this problem from clinical treatment trials is confounded by a number of issues, including the relatively small size of clinical trials, exclusion criteria for study participation, and active surveillance for liver injury. Advances in understanding the pathogenesis of drug-induced liver injury, as well as its prevention and treatment, will likely require the identification and careful characterization of severe cases in the post-marketing, real-world setting as part of a concerted, multi-center, well-orchestrated effort. The Drug-Induced Liver Injury Network (DILIN) represents one example of such an effort.",
author = "Davern, {Timothy J.} and Naga Chalasani",
year = "2009",
month = "5",
doi = "10.1038/ajg.2009.76",
language = "English",
volume = "104",
pages = "1159--1161",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Editorial

T2 - Drug-induced liver injury in clinical trials: As rare as hens teeth

AU - Davern, Timothy J.

AU - Chalasani, Naga

PY - 2009/5

Y1 - 2009/5

N2 - Severe drug-induced liver injury is a relatively rare but important public health problem. Extrapolating the incidence of this problem from clinical treatment trials is confounded by a number of issues, including the relatively small size of clinical trials, exclusion criteria for study participation, and active surveillance for liver injury. Advances in understanding the pathogenesis of drug-induced liver injury, as well as its prevention and treatment, will likely require the identification and careful characterization of severe cases in the post-marketing, real-world setting as part of a concerted, multi-center, well-orchestrated effort. The Drug-Induced Liver Injury Network (DILIN) represents one example of such an effort.

AB - Severe drug-induced liver injury is a relatively rare but important public health problem. Extrapolating the incidence of this problem from clinical treatment trials is confounded by a number of issues, including the relatively small size of clinical trials, exclusion criteria for study participation, and active surveillance for liver injury. Advances in understanding the pathogenesis of drug-induced liver injury, as well as its prevention and treatment, will likely require the identification and careful characterization of severe cases in the post-marketing, real-world setting as part of a concerted, multi-center, well-orchestrated effort. The Drug-Induced Liver Injury Network (DILIN) represents one example of such an effort.

UR - http://www.scopus.com/inward/record.url?scp=66949121802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949121802&partnerID=8YFLogxK

U2 - 10.1038/ajg.2009.76

DO - 10.1038/ajg.2009.76

M3 - Article

VL - 104

SP - 1159

EP - 1161

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -